Adding subcutaneous insulin degludec early to IV insulin may accelerate diabetic ketoacidosis resolution and improve glycemic outcomes without added risk.
A new analysis of national inpatient data reveals that women with both diabetes and polycystic ovary syndrome (PCOS) experience similar hospital outcomes to those without PCOS but face a significantly lower...
A phase 3 trial confirms that combining ibrutinib with venetoclax yields superior measurable residual disease clearance, progression-free survival, and overall survival in patients with chronic lymphocytic...
Nestoras Mathioudakis, MD, MHS, shares findings from a randomized controlled trial comparing a fully automated, app-based diabetes prevention program with a standard CDC-recognized intervention,...
In this expert interview, Tugce Akcan, MD, discusses a novel approach to type 1 diabetes care using OpenAPS and GLP-1 receptor agonists to eliminate the need for prandial insulin boluses and improve patient...
A study presented at the 85th Scientific Sessions of the American Diabetes Association explored how physical and cognitive limitations affect glucometer use in adults aged 65 years and older with type 2...
In a phase 3 trial, tolebrutinib, an oral Bruton’s tyrosine kinase inhibitor, significantly reduced the risk of sustained disability progression in patients with nonrelapsing secondary progressive multiple...
Researchers found that the combination of benmelstobart, chemotherapy, and anlotinib yields improved response and progression-free survival in patients with advanced or recurrent endometrial cancer,...
A phase 2 study evaluating the safety and efficacy of letrozole, abemaciclib, and metformin in treating estrogen receptor–positive recurrent endometrial cancer highlights promising outcomes in a select...
